Allosteric Modulators of Src-family Kinases for Acute Myeloid Leukemia

急性髓系白血病 Src 家族激酶的变构调节剂

• 批准号: 10314948
• 负责人: Ari Selzer
• 金额: $ 3万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10314948
• 关键词: 3-Dimensional; Active Sites; Acute Myelocytic Leukemia; Adult; Apoptosis; Bcr-Abl tyrosine kinase; Binding; Binding Sites; Biological Assay; Cell Line; Cell Proliferation; Cell Survival; Cells; Chronic Myeloid Leukemia; Clinic; Clinical; Complex; Crystallization; Data; Development; Diamines; Disease; Docking; Drug Targeting; Family member; Fellowship; Future; Gleevec; Growth; Hematopoietic; Hematopoietic Neoplasms; Imatinib; In Vitro; Investigation; Lead; Length; Link; Malignant Neoplasms; Mammals; Mitosis; Modeling; Molecular Conformation; Mutation; Myelogenous; N-terminal; Nucleic Acid Regulatory Sequences; Patients; Pharmaceutical Chemistry; Pharmacology; Pharmacotherapy; Phosphotransferases; Point Mutation; Predisposition; Prognosis; Property; Protein Tyrosine Kinase; Pyrimidine; Receptor Protein-Tyrosine Kinases; Recombinants; Regulation; Resistance; Roentgen Rays; Role; SH3 Domains; Sampling; Severities; Signal Pathway; Signal Transduction; Site; Specificity; Structure; Surface Plasmon Resonance; Survival Rate; Testing; Therapeutic; Tissues; Treatment Efficacy; Treatment Failure; Tyrosine Kinase Inhibitor; Work; X-Ray Crystallography; acute myeloid leukemia cell; base; cancer initiation; cell growth; cell motility; experimental study; high throughput screening; improved; in silico; in vitro testing; in vivo; inhibitor/antagonist; insight; kinase inhibitor; mRNA Differential Displays; member; mouse model; mutant; novel; novel drug class; novel strategies; organizational structure; overexpression; progenitor; resistance mutation; response; side effect; small molecule; src Homology Region 2 Domain; src-Family Kinases; synergism; therapeutic target; tumor progression; virtual

Abstract The eight mammalian Src-family members are non-receptor protein-tyrosine kinases which are involved in nearly all cell signaling pathways. Hck and Fgr are members of this family expressed almost exclusively in myeloid hematopoietic cells and their progenitors. The overexpression of these kinases has been linked to the development of, and a poorer prognosis in, acute myeloid leukemia (AML). AML is a common form of blood cancer in adults, with nearly 20,000 new cases per year in the US. About one-third of AML cases have activating mutations in the Flt3 receptor tyrosine kinase, including point mutations and internal tandem duplications. Current treatments for this subset of AML patients include ATP-site kinase inhibitors, although acquired resistance mutations commonly develop within one year of the start of treatment. Inhibitors for Hck and Fgr are also emerging as a new approach to AML therapy. Our group recently identified small molecules that bind to the regulatory domains of Hck (unique-SH3-SH2-linker) as opposed to the ATP-binding site of the kinase domain. Binding data and docking models suggest that these compounds bind to a site that requires a specific 3D- conformation of the SH3 and SH2 domains. They also decrease the viability of an AML cell line that overexpresses active Hck and Fgr. Based on these results, we hypothesize that these compounds suppress AML cell growth by interfering with downstream signaling via the SH3 and SH2 domains. In addition, the compounds may allosterically influence the conformation of the active site to favor ATP-site inhibitor action. We aim to expand upon these findings using in vitro kinase and binding assays to explore selectivity within the Src- kinase family and possible synergy with ATP-site inhibitors. The anti-AML mechanism of action of the compounds will be tested in AML cell line models by correlating their effects on kinase activity and downstream substrate activation with growth suppression and apoptosis. Finally, we will determine the binding site for these putative allosteric inhibitors within Hck by X-ray crystallography. These experiments will provide crucial insight for the future development of these novel compounds as a treatment for AML, either as stand-alone therapy or in combination with existing ATP-site inhibitors. 1

抽象的 八个哺乳动物SRC家庭成员是非受体蛋白 - 酪氨酸激酶，几乎涉及 所有细胞信号通路。 HCK和FGR是这个家庭的成员，几乎完全在髓样中表达 造血细胞及其祖细胞。这些激酶的过表达与 急性髓样白血病（AML）的发展和预后较差。 AML是一种常见的血液形式 成人的癌症，美国每年有近20,000例新病例。大约三分之一的AML病例激活 FLT3受体酪氨酸激酶中的突变，包括点突变和内部串联重复。当前的 AML患者该子集的治疗包括ATP位点激酶抑制剂，尽管获得了抗药性 通常在治疗开始后的一年内发生突变。 HCK和FGR的抑制剂也是 成为AML治疗的新方法。我们的小组最近确定了与 与激酶域的ATP结合位点相反，HCK（独特的SH3-SH2链链）的调节域。 绑定数据和对接模型表明，这些化合物与需要特定3D-的位点结合 SH3和SH2域的构象。它们还降低了AML细胞系的生存能力 过表达活动的HCK和FGR。基于这些结果，我们假设这些化合物抑制了 通过通过SH3和SH2结构域干扰下游信号传导，AML细胞生长。另外， 化合物可能会在活性位点的构象上变构，以有利于ATP位置抑制剂作用。我们 旨在使用体外激酶和结合测定来扩展这些发现，以探索SRC-内的选择性 激酶家族和可能与ATP位点抑制剂协同作用。反AML作用机理 通过将其对激酶活性和下游的影响相关联，将在AML细胞系模型中测试化合物 生长抑制和凋亡的底物激活。最后，我们将确定这些绑定位点 X射线晶体学内HCK中的推定变构抑制剂。这些实验将提供至关重要的见解 为了将这些新颖化合物作为AML的未来开发，无论是独立治疗还是 结合现有的ATP位置抑制剂。 1